| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/24/2005 | WO2004094400A3 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 02/24/2005 | WO2004087195A3 Therapeutic use of modulators of notch and/or kruppel-like factors |
| 02/24/2005 | WO2004031413A3 Method for diagnosing non-small cell lung cancers |
| 02/24/2005 | WO2004024088A3 Design of chemokine analogs for the treatment of human diseases |
| 02/24/2005 | WO2004015062A3 Methods and compositions relating to gene silencing |
| 02/24/2005 | WO2003059273A3 Antibody-avidin fusion proteins as cytotoxic drugs |
| 02/24/2005 | WO2003018758A3 Reagents and methods for smooth muscle therapies |
| 02/24/2005 | WO2002074237A8 Compositions and methods for the therapy and diagnosis of kidney cancer |
| 02/24/2005 | US20050043788 Drug-eluting stent |
| 02/24/2005 | US20050043549 Novel diterpene compounds |
| 02/24/2005 | US20050043544 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 02/24/2005 | US20050043534 Modulators of ceramidase and methods of used based thereon |
| 02/24/2005 | US20050043516 TACI antibodies and uses thereof |
| 02/24/2005 | US20050043512 Human glioma antigen originating in testis |
| 02/24/2005 | US20050043481 Material consisting of at least a biodegradable polymer and cyclodextrins |
| 02/24/2005 | US20050043409 Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 02/24/2005 | US20050043398 such as 2-ethoxycarbonyl-7-hydroxychromone, for the care, preservation or improvement of the general state of the skin or hair |
| 02/24/2005 | US20050043395 Angiogenesis inhibitors; reduced vascular system permeability; anticancer agents; antitumor agents |
| 02/24/2005 | US20050043394 For prophylaxis and therapy of diabetes mellitus, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases, neuropathic diseases, neuropathic pain and polyneuropathy; free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate, deoxyuridine monophosphate |
| 02/24/2005 | US20050043386 2-amino-2-(ethyl or methyl)-4-{5-substituted pyrrol-2-yl}butan-1-ols, phosphates and phosphonates; antiarthritic agents; psoriasis; immunosuppressants |
| 02/24/2005 | US20050043381 Aminopyrazole compounds |
| 02/24/2005 | US20050043362 Use of compounds |
| 02/24/2005 | US20050043357 Mitotic kinesin inhibitors |
| 02/24/2005 | US20050043356 Polymorphic form of rimonabant method for preparing it and pharmaceutical compositions containing it |
| 02/24/2005 | US20050043355 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| 02/24/2005 | US20050043352 human YAK family of serine/threonine protein kinases (hyak); use treating diseases of the hematopoietic systems, including anemias, polycythemia, myelodysplastic syndrome, myelosuppression, cytopenia, male contraceptives; 2-(3-Chloro-phenylamino)-7-methoxy-quinoline-3-carboxylic acid for example |
| 02/24/2005 | US20050043350 Administering heterocyclic ether such as 5-chloro-7-hydroxy-3-(4-hydroxyphenylz)-4-oxo-1-benzopyran for prophylaxis of Alzheimer's disease, osteoporosis, cardiovascular disorders, psychological disorders, antiarthritic agents,anxiolytic agents |
| 02/24/2005 | US20050043346 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/24/2005 | US20050043344 Such as 3-(3,5-ditert-butylphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid; for treatment of tumor metastasis, angiogenesis, osteoporosis, arthritis, retinopathy, smooth muscle cell migration, restenosis, and atheroscelorosis |
| 02/24/2005 | US20050043340 Process for reacting alkaloids and use of the reaction products in the preparation of medicaments |
| 02/24/2005 | US20050043336 Quinazoline derivatives as antitumor agents |
| 02/24/2005 | US20050043333 Quinazolinone derivative |
| 02/24/2005 | US20050043330 Antiinflammation agents |
| 02/24/2005 | US20050043328 Such as 6-(2-hydroxy-3-chloroxybenzylamino)purine, 6-(2-hydroxy-4-chlorobenzylamino)purine; agriculture; cloning; immunostimulation |
| 02/24/2005 | US20050043299 Inhibitors of dipeptidyl peptidase iv |
| 02/24/2005 | US20050043285 Formulation |
| 02/24/2005 | US20050043281 administering for treatment of metabolic bone diseases, mobilizing calcium for osteoporosis, imbalances in the immune system |
| 02/24/2005 | US20050043269 Pharmaceutically active uridine esters |
| 02/24/2005 | US20050043241 Use of inhibitors of given amino acid sequence; inhibit phosphorylation of a transcription factor; can be used to treat or prevent diabetes, ionizing radiation damage, autoimmune diseases, ischemia/reperfusion injuries, heart hypertrophies, cancer |
| 02/24/2005 | US20050043233 Comprising an antagonist of at least one receptor selected from VEGFR 1 to 3, PDGFR alpha and beta , FGFR1, 2 and 3, EGFR, HER2, IGF1R, HGFR or c-Kit, which is further an antagonist of a src tyrosine kinase family member, and a chemotherapeutic agent; co-treatment with radiation therapy |
| 02/24/2005 | US20050043230 Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases |
| 02/24/2005 | US20050043226 having a building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thioester, or disulfide; used to treat cancers, diabetes, diabetic-associated complications, endocrine disorders, gastrointestinal disorders, and pancreatitis |
| 02/24/2005 | US20050043224 Administering to patient a pharmaceutical preparation comprising at least one chemoprotective inducing agent and a vehicle for delivering chemoprotective inducing agent to cells lining hair follicles, in an amount and for a time effective to reduce or prevent hair loss |
| 02/24/2005 | US20050042738 Carbohydrate-associated proteins |
| 02/24/2005 | US20050042731 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders |
| 02/24/2005 | US20050042680 Single chain antigen-binding polypeptides for polymer conjugation |
| 02/24/2005 | US20050042671 Modulation of angiogenesis |
| 02/24/2005 | US20050042667 Expression vector comprising nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of immune, hematopoietic, inflammatory and tumor diseases |
| 02/24/2005 | US20050042655 Using hematopoietoic regulatory related polypeptide (HEMA) for use in diagnosis, treatment and prevention of hematopoietic disorders |
| 02/24/2005 | US20050042653 Human transport protein homologs |
| 02/24/2005 | US20050042650 EN2 gene, diagnostic and therapeutic uses thereof |
| 02/24/2005 | US20050042624 Tumor antigen |
| 02/24/2005 | US20050042614 Point mutations; dipeptidyl-peptidase inhibitors; kits |
| 02/24/2005 | US20050042317 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/24/2005 | US20050042315 Paget's disease; antitumor agents; osteoporesis; nutrient mixture of plant extract and calcium compound |
| 02/24/2005 | US20050042303 Therapeutic protocols |
| 02/24/2005 | US20050042279 Pharmaceutical formulation comprising more than 15% tamoxifen |
| 02/24/2005 | US20050042273 Covalently linking PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; diagnostic and therapeutic agent; improving pharmacokinetic properties |
| 02/24/2005 | US20050042237 Method for administering a spill resistant pharmaceutical system |
| 02/24/2005 | US20050042225 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 02/24/2005 | US20050042209 Enhancing the induction apoptosis in a MUC1 expressing cancer cell by a pro-apoptotic drugs; antiproliferative agents |
| 02/24/2005 | US20050042208 Incubating precursor cell capable of differentiating to cytotoxic T cell with antigen presenting cell in presence of substance having binding activity to CD44, fibronectin, regulator of signal emitted by growth factor, and/or inhibitor of binding to growth factor receptor; immunotherapy |
| 02/24/2005 | US20050042201 Synergistic mixture of glycoprotein and angiogenesis inhibitor comprising angiostatin, thrombostatin, endostatin, interferon, interferon-inducible factor 10, platelet factor, and/or cyclooxygenase inhibitor; antitumor and anticarcinogenic agents |
| 02/24/2005 | US20050042199 Comprising interleukin-2 (IL-2) and tlp peptides ( Tumour Liberated Particles) protein complexes; antitumor and anticarcinogenic agents; immunotherapy |
| 02/24/2005 | DE10331500A1 Neue Acridin-Derivate und deren Verwendung als Arzneimittel New acridine derivatives and their use as medicaments |
| 02/24/2005 | CA2536518A1 Proteasome inhibitors and methods of using the same |
| 02/24/2005 | CA2536470A1 Pyrrole compositions useful as inhibitors of c-met |
| 02/24/2005 | CA2536146A1 Splice variants of erbb ligands, compositions and uses thereof |
| 02/24/2005 | CA2536140A1 Dosing schedule for erbb2 anticancer agents |
| 02/24/2005 | CA2535652A1 Substituted thiophenes and uses thereof |
| 02/24/2005 | CA2535620A1 6-substituted anilino purines as rtk inhibitors |
| 02/24/2005 | CA2535619A1 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| 02/24/2005 | CA2535584A1 Platinum complexes for the treatment of tumors |
| 02/24/2005 | CA2535416A1 Imidazopyridine derivatives |
| 02/24/2005 | CA2534563A1 Antibodies to c-met |
| 02/24/2005 | CA2534436A1 Antagonistic analogs of gh-rh (2003) |
| 02/24/2005 | CA2534300A1 Aminopyrones and their use as atm inhibitors |
| 02/24/2005 | CA2534215A1 Methods of therapy for chronic lymphocytic leukemia |
| 02/24/2005 | CA2534197A1 Use of a vegf antagonist in combination with radiation therapy |
| 02/24/2005 | CA2533382A1 Etherified carbamate functional copolymers of isobutylene type monomers, and their use in curable compositions |
| 02/24/2005 | CA2532027A1 Specific binding agents to hepatocyte growth factor |
| 02/24/2005 | CA2525647A1 Synthetic chemokine receptor ligands and methods of use thereof |
| 02/24/2005 | CA2524737A1 Antibodies that immunospecifically bind to trail receptors |
| 02/24/2005 | CA2524305A1 Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| 02/23/2005 | EP1508570A1 Novel physiolgically active substances |
| 02/23/2005 | EP1508334A1 Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract |
| 02/23/2005 | EP1508333A1 Novel therapeutic use of riboside of 5-aminoimidazole-4- carboxamide (acadesine) |
| 02/23/2005 | EP1508331A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection |
| 02/23/2005 | EP1508327A1 Use of chromen-4-one derivatives for the care of skin and hair |
| 02/23/2005 | EP1508047A2 Method for identifying immunoreactive peptides |
| 02/23/2005 | EP1507861A2 Vaccines |
| 02/23/2005 | EP1507850A1 A method for generating antigen-presenting cells |
| 02/23/2005 | EP1507794A2 Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments |
| 02/23/2005 | EP1507790A2 Human genes and gene expression products isolated from human prostate |
| 02/23/2005 | EP1507781A2 Process for preparing maytansinol |
| 02/23/2005 | EP1507780A1 Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| 02/23/2005 | EP1507779A1 Inhibitors of jak and cdk2 protein kinases |
| 02/23/2005 | EP1507778A1 Anti-tumour polycyclic carboxamides |
| 02/23/2005 | EP1507776A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| 02/23/2005 | EP1507773A1 Macrocyclic compounds useful as pharmaceuticals |